Cardiothoracic & vascular anesthesia

Preoperative neutrophil–to–lymphocyte ratio after chemoradiotherapy for esophageal squamous cell carcinoma associates with postoperative pulmonary complications following radical esophagectomy

Perioper Med (Lond)Published Retrospective cohort study

Authors' conclusion

Elevated preoperative neutrophil-to-lymphocyte ratio after chemoradiotherapy is independently associated with higher pulmonary complication rate following radical esophagectomy and poor prognosis in patients with esophageal squamous cell carcinoma receiving preoperative chemoradiotherapy.

Study context

Population
Stage III esophageal squamous cell carcinoma patients receiving preoperative chemoradiotherapy followed by esophagectomy, January 2009–December 2017
Participants
111 consecutive patients
Exposure
Preoperative neutrophil-to-lymphocyte ratio ≥ 3 vs < 3
Outcome
Pulmonary complications following radical esophagectomy
Methodological detailsconsecutive patients
  • Consecutive patients

Main finding

As reported in the abstract

Pulmonary complications

P = 0.008

Observational data: associations, not effects.

Further findings

Overall survival · 3 years

P = 0.0026

Disease-free survival · 3 years

P = 0.0055

Postoperative complications, overall (all patients)

Any postoperative complication
75 (68%)
Pulmonary complications
32 (29%)

Other factors associated with pulmonary complications

Clinical T4 classification
P = 0.007
Advanced stage IIIC
P = 0.012

Oncological stratification (pathological T, N, AJCC stage)

Preoperative NLR not associated with pathological T, N classification or AJCC stage

Original publication

Preoperative neutrophil–to–lymphocyte ratio after chemoradiotherapy for esophageal squamous cell carcinoma associates with postoperative pulmonary complications following radical esophagectomy. Perioper Med (Lond). Published 2 July 2024. doi:10.1186/s13741-024-00431-6

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.